Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease

Heart Lung and Circulation

Volumn 15, Issue 2, 2006, Pages 139-142

  Kuroda, Tadashi ^a   Hirota, Hisao ^a   Masaki, Mitsuru ^a   Sugiyama, Shoko ^a   Oshima, Yuichi ^a   Terai, Kazuo ^a   Ito, Akihiko ^a   Yamauchi Takihara, Keiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Prostacyclin; Pulmonary hypertension; Pulmonary veno occlusive disease; Sildenafil

Indexed keywords

DOBUTAMINE; DOPAMINE; FUROSEMIDE; MILRINONE; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG MEGADOSE; FLUSHING; HEMODYNAMICS; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SKIN MANIFESTATION;

EID: 33646161445     PISSN: 14439506     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hlc.2005.07.002     Document Type: Article

References (6)

1. Holcomb BW, Loyd JE, Ely EW, Johnson J, Robbins IM. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000;118:1671-9.
2. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998;113:237-40.
3. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-403.
4. Okumura H, Nagaya N, Kyotani S, Sakamaki F, Nakanishi F, Fukuhara S, et al. Effects of continuous iv prostacyclin in a patient with pulmonary veno-occlusive disease. Chest 2002;122:1096-8.
5. Davis LL, deBoisblane BP, Glynn CE, Ramirez C, Summer WR. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest 1995;108: 1754-6.
6. Eckly AE, Lugnier C. Role of phosphodiesterase III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br J Pharmacol 1994;113:445-50.